Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Emergent BioSolutions has formally inaugurated a 6,000sqft manufacturing facility at Baltimore. The new facility includes multiple manufaturing suites to support clinical and commercial manufacturing of company's rPA, anthrax monoclonal and tuberculosis product candidates, among others.
Subscribe to our email newsletter
Emergent said that its Baltimore manufacturing facility could create an additional 120 jobs in the next five years.
Emergent is currently working on modifying and re-commissioning the facility. Planned facility modifications will allow for the utilisation of disposable manufacturing technology to potentially result in lower capital investments, lower operating costs, and accelerated process development timelines.
O’Malley, governor of Maryland, said: “Emergent’s expansion into Baltimore, through the purchase and re-commissioning of this facility, enables significant investment in the biotech infrastructure already in place and ensures that high-paying, highly-skilled jobs are created and remain in Maryland.”
Emergent BioSolutions is a biopharmaceutical company focused on the development, manufacture and commercialisation of vaccines and antibody therapies that assist the body’s immune system to prevent or treat disease.